Thyroid Hormone for Thyroid Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

August 31, 2026

Conditions
Differentiated Thyroid CancerThyroid CancerLevothyroxineLiothyronineThyroid Hormones
Interventions
DRUG

Euthyrox (levothyroxine)

Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.

DRUG

Cytomel (liothyronine)

Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The pharmacoequivalent ratio of L-T3 to L-T4 is 1:3. The L-T4-cohort receive doses of 2 μg × kg body weight / day. The pharmacoequivalent L-T3 dose would be 1/3th of that namely: 0.67 μg × kg body weight / day. Cytomel will be given trice daily and available dosages are 5, 12.5 and 25 μg.

Trial Locations (2)

9700RB

University Medical Center Groningen (UMCG), Groningen

Unknown

Radboud University Nijmegen, Nijmegen

All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

lead

University Medical Center Groningen

OTHER